Abstract: In certain embodiments, a method includes obtaining a cloud-based application; extracting native language files and internationalization keys that correspond to the native language files from the cloud-based application; storing the native language files and the keys in a translation data repository accessible by a translation service; detecting non-native language files corresponding to the native language files in the translation data repository; performing an initial check on the non-native language files; generating, when the initial check passes, a test build of the cloud-based application; deploying the test build to a test environment in a cloud infrastructure to have a first validation performed by the translation service and a second validation performed by a cloud-based application provider; and generating, when the first validation and the second validation pass, a production build of the cloud-based application comprising the non-native language files.

Abstract: A user input device includes an optical window facing onto a region of skin of the user when the user input device is in normal use, a monochromatic light source arranged to emit light through the optical window, a spectral dispersal unit adapted to disperse the spectrum of light reflected back from the region of skin of the user, the reflected light no longer being wholly monochromatic due to Raman scattering, and a light sensor operable to detect at least some of the dispersed spectrum of light and output corresponding light data.

Abstract: A device controls a power flow in an AC network and has a series converter with a DC side to connect to a DC link and an AC side to connect to the AC network via a series transformer. The device further has a bridging arrangement between the series transformer and the series converter configured to bridge the series converter. The bridging arrangement contains at least one bridging branch having a switching unit with antiparallel thyristors and a resistance in series with the switching unit. Furthermore, a method of operation operates the device.

Abstract: Disclosed herein, among other things, are apparatus and methods for a hearing assistance device housing for biometric sensing. In various embodiments, a hearing assistance device for a wearer includes a housing customized to conform to a continuous section of an inner portion of an ear of the wearer and to extend radially to one or more edges of a conchal bowl of the ear. The housing is configured to be placed in the inner portion of the ear of the wearer, and a biometric sensor is included on a surface of the housing. According to various embodiments, the housing is configured to maintain contact of the biometric sensor with the inner portion of the ear of the wearer during activity of the wearer, to enhance accuracy of biometric sensing.

Abstract: Various embodiments of a hearing device and a method of using such device are disclosed. The hearing device includes a housing having an inner surface and an outer surface, electronic components disposed within the housing, and a port disposed in the housing and extending between a first end at the outer surface of the housing and a second end disposed within the housing, where the port is acoustically connected to at least one of a speaker or a microphone of the electronic components. The hearing components also include a controller that is electrically connected to a sensor and that is adapted to detect a change in capacitance of the sensor, where the change in capacitance is associated with debris at least partially occluding the port.

Abstract: A method for manufacturing a hearing instrument includes placing a component support structure at least partially in a bath of a resin liquid, wherein one or more operative components of the hearing instrument are attached to or contained within the component support structure prior to the component support structure being at least partially placed in the bath of the resin liquid. While the component support structure is at least partially in the bath, volumetric 3-dimensional (3D) printing is performed to form a shell of the hearing instrument attached to the component support structure.

Abstract: In one embodiment, a method of automated missile launcher reloading includes aligning one or more collars of a shelving system with a path of a canister and activating one or more rollers of the shelving system to translate the canister into the one or more collars. The method also includes coupling a first collar of the one or more collars to the canister and adjusting the one or more collars to align the canister with a path of a launcher cell. The method further includes translating the one or more collars into the path of the launcher cell to feed the canister into the launcher cell.

Abstract: In one embodiment, a method of automated missile launcher reloading includes positioning a canister positioning device proximate to a canister. The canister positioning device is coupled to a pivot arm by one or more pivot joints and the pivot arm is coupled to a tower. The method also includes coupling the canister positioning device to the canister, attaching a hoist cable to the canister, and raising the pivot arm on the tower from a first position on the tower to a second position on the tower. The method further includes adjusting a positioning of the pivot arm to position the canister proximate to a launcher cell, adjusting a positioning of the pivot joints to align the canister with the launcher cell, and lowering the hoist cable to lower the canister into the launcher cell.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: An example system includes an ear-wearable device comprising a housing and a rechargeable battery located within the housing; a supplemental power storage device configured to provide electrical energy; and circuitry configured to transfer, responsive to occurrence of an event, electrical energy from the supplemental power storage device to the rechargeable battery prior to an initial use of the ear-wearable device.

Abstract: A method for fitting a hearing instrument comprises obtaining sensor data from a plurality of sensors belonging to a plurality of sensor types; applying a machine learned (ML) model to determine, based on the sensor data, an applicable fitting category of the hearing instrument from among a plurality of predefined fitting categories, wherein the plurality of predefined fitting categories includes a fitting category corresponding to a correct way of wearing the hearing instrument and a fitting category corresponding to an incorrect way of wearing the hearing instrument; and generating an indication based on the applicable fitting category of the hearing instrument.

Abstract: Provided are electric vehicle charging systems and methods of operating such systems for charging electric vehicles (EVs). A system comprises one or more EV charging ports (e.g., charge handles) for connecting to EVs. The system may include various features to identify specific EVs. The system also includes a grid connector for connecting to an external power grid and, in some examples, to monitor the power grid conditions (e.g., voltage, AC frequency). The system also includes a system controller, configured to control the power output at each EV charging port based on, e.g., vehicle charging requirements and/or available grid power. The system can also include an integrated battery, serving as a backup and/or an addition to the power grid. Furthermore, in some examples, the system includes a solar connector (e.g., with an integrated inverter) for connection to an external solar array.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: A system may have a rechargeable hearing instrument with a power source, an ultraviolet (UV) sensor configured to convert received UV light into electrical power and charging circuitry coupled to the UV sensor and to the power source. The charging circuitry may use the electrical power to charge the power source. A charger may have a charging cavity configured to receive the rechargeable hearing instrument. A power source within the charger powers a UV light source located within the charger configured to provide UV light to the UV sensor of the rechargeable hearing instrument when the rechargeable hearing instrument is placed within the charging cavity.

Abstract: A bed is provided. The bed includes a plurality of wheels contacting the floor, a frame supported by the plurality of wheels, a support deck supported by the frame and having a head end, a foot end, a first side extending between the head end to the foot end, and a second side extending between the head end to the foot end, the support deck being expandable in a transverse extent from the first side to the second side from a first size to a second size, the second size having a larger area than the first size, and an assembly coupled to the support deck, the assembly including a single powered mechanical actuator which expands the support deck from the first size to the second size.

Abstract: Provided are electric vehicle charging systems (EV charging systems) and methods of operating such systems for charging electric vehicles (EVs). A system, which may be referred to as electric vehicle service equipment (EVSE), comprises one or more EV charging ports (e.g., charge handles) for connecting to EVs. The system may include various features to identify specific EVs. The system also includes a grid connector for connecting to an external power grid and, in some examples, to monitor the power grid conditions (e.g., voltage, AC frequency). The system also includes a system controller, configured to control the power output at each EV charging port based on, e.g., vehicle charging requirements and/or available grid power. The system can also include an integrated battery, serving as a backup and/or an addition to the power grid. Furthermore, in some examples, the system includes a solar connector (e.g., with an integrated inverter) for connection to an external solar array.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.